×

What are you searching for?




Healthcare

4 Min read

ALEMBIC PHARMA'S ARM GETS USFDA TENTATIVE APPROVAL FOR DRUG TO TREAT PAH

Published On 07 Sep 2020 08:03 PM


SHARE THIS ARTICLE  


Highlights

• Pulmonary arterial hypertension (PAH) affects arteries in the lungs and in the heart

• As per the reports, this newly approved drug is therapeutically equivalent to the reference listed drug product Remodulin injection which has been developed by United Therapeuyics Corp

• After receiving this approval for its Treprostinil injection, Alembic currently has total 131 ANDA approvals (113 f....


Tags : USFDA, Alembic Pharmaceuticals, Pulmonary arterial hypertension, FDA, Remodulin, ,
SHARE THIS ARTICLE  

Leave a comment 

comments (0)